ACXP
Acurx Pharmaceuticals, Inc.
Biotechnology
Market Cap$5M
5Y Perf.-98.3%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
ACXP vs LPSN
Revenue, margins, valuation, and 5-year total return — side by side.
LPSN
LivePerson, Inc.
Software - Application
Market Cap$32M
5Y Perf.-99.7%
ACXP vs LPSN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ACXP | LPSN |
|---|---|---|
| Industry | Biotechnology | Software - Application |
| Market Cap | $5M | $32M |
| Revenue (TTM) | $0.00 | $244M |
| Net Income (TTM) | $-7.97B | $-67M |
| Gross Margin | — | 62.2% |
| Operating Margin | — | -9.6% |
| Total Debt | $0.00 | $392M |
| Cash & Equiv. | $7.56B | $95M |
ACXP vs LPSN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ACXP
LPSN
| Stock | Jun 21 | May 26 | Return |
|---|---|---|---|
| Acurx Pharmaceutica… (ACXP) | 100 | 1.7 | -98.3% |
| LivePerson, Inc. (LPSN) | 100 | 0.3 | -99.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ACXP vs LPSN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: LPSN leads in 2 of 4 categories, making it the strongest pick for capital preservation and lower volatility and operational efficiency and capital deployment. Acurx Pharmaceuticals, Inc. is the stronger pick specifically for recent price momentum and sentiment. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
ACXP
Acurx Pharmaceuticals, Inc.
The Growth Play
ACXP is the clearest fit if your priority is growth exposure.
- EPS growth 69.8%
- -70.1% vs LPSN's -77.1%
Best for: growth exposure
LPSN
LivePerson, Inc.
The Income Pick
LPSN carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 2.05
- -97.0% 10Y total return vs ACXP's -98.7%
- Lower volatility, beta 2.05, current ratio 1.12x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Stability / Safety | LPSN | Beta 2.05 vs ACXP's 2.42 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | ACXP | -70.1% vs LPSN's -77.1% |
| Efficiency (ROA) | LPSN | -12.4% ROA vs ACXP's -413.5% |
ACXP vs LPSN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
ACXP vs LPSN — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLACXPLAGGINGLPSN
LPSNLivePerson, Inc.
1leads
ACXPAcurx Pharmaceuticals…
2leads
6 Total Categories
CATEGORYLEADERvs LPSNMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ACXP1/1
Valuation MetricsMultiples, price ratios, and targets
ACXP1/1
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
Tied
—
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
LPSN2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ACXP leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
LPSN and ACXP operate at a comparable scale, with $244M and $0 in trailing revenue.
| Metric | ACXPAcurx Pharmaceuti… | LPSNLivePerson, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $0 | $244M |
| EBITDAEarnings before interest/tax | $35,910 | -$562,000 |
| Net IncomeAfter-tax profit | -$8.0B | -$67M |
| Free Cash FlowCash after capex | $4.6B | -$43M |
| Gross MarginGross profit ÷ Revenue | — | +62.2% |
| Operating MarginEBIT ÷ Revenue | — | -9.6% |
| Net MarginNet income ÷ Revenue | — | -27.6% |
| FCF MarginFCF ÷ Revenue | — | -17.4% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -19.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +98.2% | +79.4% |
ACXP leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
ACXP leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | ACXPAcurx Pharmaceuti… | LPSNLivePerson, Inc. |
|---|---|---|
| Market CapShares × price | $5M | $32M |
| Enterprise ValueMkt cap + debt − cash | -$7.6B | $329M |
| Trailing P/EPrice ÷ TTM EPS | -0.40x | -0.22x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 0.13x |
| Price / BookPrice ÷ Book value/share | 0.00x | — |
| Price / FCFMarket cap ÷ FCF | — | — |
ACXP leads this category, winning 1 of 1 comparable metric.
Profitability & Efficiency
Evenly matched — ACXP and LPSN each lead in 2 of 4 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), LPSN scores 5/9 vs ACXP's 3/9, reflecting solid financial health.
| Metric | ACXPAcurx Pharmaceuti… | LPSNLivePerson, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -6.0% | — |
| ROA (TTM)Return on assets | -4.1% | -12.4% |
| ROICReturn on invested capital | — | -6.6% |
| ROCEReturn on capital employed | — | -5.8% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 5 |
| Debt / EquityFinancial leverage | — | — |
| Net DebtTotal debt minus cash | -$7.6B | $297M |
| Cash & Equiv.Liquid assets | $7.6B | $95M |
| Total DebtShort + long-term debt | $0 | $392M |
| Interest CoverageEBIT ÷ Interest expense | — | 0.20x |
Evenly matched — ACXP and LPSN each lead in 2 of 4 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — ACXP and LPSN each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ACXP five years ago would be worth $134 today (with dividends reinvested), compared to $35 for LPSN. Over the past 12 months, ACXP leads with a -70.1% total return vs LPSN's -77.1%. The 3-year compound annual growth rate (CAGR) favors LPSN at -65.4% vs ACXP's -67.4% — a key indicator of consistent wealth creation.
| Metric | ACXPAcurx Pharmaceuti… | LPSNLivePerson, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | -23.2% | -31.1% |
| 1-Year ReturnPast 12 months | -70.1% | -77.1% |
| 3-Year ReturnCumulative with dividends | -96.5% | -95.8% |
| 5-Year ReturnCumulative with dividends | -98.7% | -99.7% |
| 10-Year ReturnCumulative with dividends | -98.7% | -97.0% |
| CAGR (3Y)Annualised 3-year return | -67.4% | -65.4% |
Evenly matched — ACXP and LPSN each lead in 3 of 6 comparable metrics.
Risk & Volatility
LPSN leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
LPSN is the less volatile stock with a 2.05 beta — it tends to amplify market swings less than ACXP's 2.42 beta. A beta below 1.0 means the stock typically moves less than the S&P 500.
| Metric | ACXPAcurx Pharmaceuti… | LPSNLivePerson, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.42x | 2.05x |
| 52-Week HighHighest price in past year | $21.00 | $21.60 |
| 52-Week LowLowest price in past year | $1.33 | $2.37 |
| % of 52W HighCurrent price vs 52-week peak | +10.1% | +12.4% |
| RSI (14)Momentum oscillator 0–100 | 40.9 | 40.3 |
| Avg Volume (50D)Average daily shares traded | 3.6M | 148K |
LPSN leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | ACXPAcurx Pharmaceuti… | LPSNLivePerson, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +100.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ACXP leads in 2 of 6 categories (Income & Cash Flow, Valuation Metrics). LPSN leads in 1 (Risk & Volatility). 2 tied.
Best OverallAcurx Pharmaceuticals, Inc. (ACXP)Leads 2 of 6 categories
Loading custom metrics...
ACXP vs LPSN: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Which is the better long-term investment — ACXP or LPSN?
Over the past 5 years, Acurx Pharmaceuticals, Inc.
(ACXP) delivered a total return of -98. 7%, compared to -99. 7% for LivePerson, Inc. (LPSN). Over 10 years, the gap is even starker: LPSN returned -97. 0% versus ACXP's -98. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — ACXP or LPSN?
By beta (market sensitivity over 5 years), LivePerson, Inc.
(LPSN) is the lower-risk stock at 2. 05β versus Acurx Pharmaceuticals, Inc. 's 2. 42β — meaning ACXP is approximately 18% more volatile than LPSN relative to the S&P 500.
03Which is growing faster — ACXP or LPSN?
On earnings-per-share growth, the picture is similar: Acurx Pharmaceuticals, Inc.
grew EPS 69. 8% year-over-year, compared to 45. 4% for LivePerson, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
04Which has better profit margins — ACXP or LPSN?
Acurx Pharmaceuticals, Inc.
(ACXP) is the more profitable company, earning 0. 0% net margin versus -27. 6% for LivePerson, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACXP leads at 0. 0% versus -9. 6% for LPSN. At the gross margin level — before operating expenses — LPSN leads at 62. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — ACXP or LPSN?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is ACXP or LPSN better for a retirement portfolio?
For long-horizon retirement investors, LivePerson, Inc.
(LPSN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Acurx Pharmaceuticals, Inc. (ACXP) carries a higher beta of 2. 42 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LPSN: -97. 0%, ACXP: -98. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between ACXP and LPSN?
These companies operate in different sectors (ACXP (Healthcare) and LPSN (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.